RSV symptoms in adults typically begin as a common cold — nasal congestion, sore throat, mild cough, and low-grade fever — and in most healthy adults resolve within 7 to 10 days. However, in adults over 60, those with asthma or COPD, and the immunocompromised, RSV can progress to bronchiolitis or pneumonia and is now recognized as a leading cause of respiratory hospitalization in older adults. RSV is contagious for 3 to 8 days on average, though immunocompromised patients can shed virus for weeks. At TrufaMED in Surfside, our multiplex respiratory panel confirms RSV in approximately 20 minutes and our physicians initiate treatment the same visit.
What RSV Looks Like in Adults
Respiratory syncytial virus (RSV) was historically considered a pediatric illness, but surveillance over the past decade has established it as a major adult respiratory pathogen. In adults, the presentation is often indistinguishable from a bad cold or a mild flu:
- Nasal congestion and rhinorrhea
- Sore throat
- Cough — initially dry, often becoming productive
- Headache
- Fatigue
- Low-grade fever (often absent in older adults)
- Wheezing, particularly in patients with underlying asthma or COPD
Unlike influenza, RSV rarely produces severe body aches or the sudden fever spikes characteristic of the flu. Symptom onset is gradual, over 2 to 3 days, which sometimes delays patients from seeking care.
Is RSV Contagious?
Yes. RSV is highly contagious and spreads through respiratory droplets, direct contact with infected secretions, and contact with contaminated surfaces, where the virus can survive for several hours. Key transmission facts:
- Incubation period is typically 4 to 6 days
- Adults are generally contagious 1 day before symptoms begin through 3 to 8 days of illness
- Immunocompromised adults can shed RSV for 3 to 4 weeks
- RSV spreads efficiently in households, daycare settings, and long-term care facilities
During the 2025–2026 season, the CDC reports RSV activity peaking between November and February in the southeastern United States, with regional variation.
Who Is at Higher Risk
Severe RSV in adults is concentrated in specific populations:
- Adults aged 60 and older, especially those over 75
- Patients with asthma, COPD, or other chronic lung disease
- Patients with congestive heart failure or coronary artery disease
- Immunocompromised patients, including transplant recipients and those on chemotherapy
- Residents of long-term care facilities
- Pregnant patients in the third trimester
In these groups, RSV can precipitate asthma and COPD exacerbations, trigger heart failure decompensation, and progress to viral pneumonia requiring hospitalization.
When to Seek Urgent Care
You should be evaluated promptly if you experience:
- Shortness of breath at rest or with mild exertion
- Wheezing that does not respond to usual inhaler use
- Oxygen saturation below 94 percent on a home pulse oximeter
- Chest tightness or pleuritic chest pain
- Fever above 102°F lasting more than 3 days
- Symptoms that initially improve and then worsen
- Any new confusion or lethargy in an older adult
Severe respiratory distress, bluish lips, or inability to speak full sentences warrants immediate emergency evaluation.
Diagnosis: Confirming RSV
Because RSV, influenza, COVID-19, and other respiratory viruses produce overlapping symptoms, clinical examination alone is insufficient. At TrufaMED, our multiplex respiratory panel tests for RSV, COVID, influenza A, and influenza B from a single nasal swab with results in approximately 20 minutes. Accurate identification matters because:
- Influenza has targeted antiviral therapy; RSV does not (outside of select hospitalized patients)
- Confirming a viral cause prevents unnecessary antibiotic use
- Public health reporting and household contact guidance differ by pathogen
- High-risk adults may benefit from closer monitoring or preemptive supportive care
Learn more about our combined COVID, flu, strep, and RSV testing panel.
Treatment Options in 2026
Treatment for RSV in adults is primarily supportive:
- Hydration — oral when tolerated, intravenous when dehydration is present
- Acetaminophen or ibuprofen for fever and discomfort
- Inhaled bronchodilators for patients with wheezing or underlying airway disease
- Systemic corticosteroids in selected patients with significant airway inflammation
- Supplemental oxygen for hypoxemia
- Nebulized hypertonic saline for patients with tenacious secretions
There is no approved oral antiviral for RSV in ambulatory adults. Ribavirin is reserved for select hospitalized, severely immunocompromised patients. Patients with fatigue and dehydration often benefit from IV hydration therapy while recovering. For patients with concurrent flu-like symptoms, our flu treatment protocol is initiated based on test results.
Recovery Timeline
Healthy adults typically recover fully within 7 to 14 days. Cough can persist for 3 to 4 weeks. Adults with underlying lung disease may experience protracted symptom worsening, and older adults hospitalized for RSV face a documented 1-year mortality approximately double that of age-matched controls.
Prevention
Two major advances have changed RSV prevention for adults in the past two seasons:
- RSV vaccines — The CDC recommends a single-dose RSV vaccine for all adults aged 75 and older, and for adults 60 to 74 at increased risk. Multiple licensed products are available.
- Maternal RSV vaccination — Recommended between 32 and 36 weeks of gestation to protect newborns during their first respiratory season
Additional prevention measures include hand hygiene, avoiding close contact with symptomatic individuals, and thorough disinfection of shared surfaces during outbreak periods.
Related Respiratory Conditions
RSV frequently co-circulates with influenza and COVID-19, and adults can be infected with more than one virus concurrently. Any older adult with respiratory symptoms should be tested to identify the specific cause. In pediatric patients, RSV remains a leading cause of bronchiolitis and hospitalization under age 2; our pediatric urgent care team evaluates infants and children seven days a week.
Frequently Asked Questions
How do I know if I have RSV and not a cold?
Clinical examination cannot reliably distinguish RSV from other respiratory viruses. A multiplex nasal swab is the only definitive way to confirm the diagnosis.
How long is RSV contagious in adults?
Most healthy adults are contagious for 3 to 8 days. Immunocompromised adults can shed virus for several weeks.
Can adults get RSV from children?
Yes. Household transmission from symptomatic children to parents and grandparents is one of the most common routes of adult RSV infection.
Is there an antiviral for RSV?
There is no approved outpatient antiviral for RSV in adults. Treatment is supportive, with bronchodilators and steroids in select cases.
Should I get the RSV vaccine?
Adults 75 and older are recommended to receive the RSV vaccine. Adults 60 to 74 with risk factors should discuss vaccination with a physician.
Can RSV come back after you recover?
Immunity after RSV infection is incomplete and short-lived. Reinfection is common, though subsequent infections are typically milder in immunocompetent adults.
How long does an RSV cough last?
Cough frequently persists for 2 to 4 weeks after the acute illness resolves, particularly in adults with underlying airway disease.
Same-Day RSV Testing at TrufaMED
If you are an older adult or have underlying lung or heart disease and develop respiratory symptoms, prompt testing and physician evaluation can prevent avoidable complications. TrufaMED is open seven days a week, 8 a.m. to 10 p.m., with a physician on site every day. Walk in at 9445 Harding Avenue in Surfside or call (305) 537-6396 to be seen the same day.
Sources: Centers for Disease Control and Prevention (CDC) RSV surveillance and vaccination recommendations, 2025–2026. New England Journal of Medicine reviews on RSV in older adults.
